BioWorld

June 6, 2002

Waksal Subpoenaed; ImClone To Face House Subcommittee

WASHINGTON - Former ImClone Systems Inc. CEO Samuel Waksal has been subpoenaed by a House subcommittee to answer questions surrounding the business transactions and development of the investigational cancer drug Erbitux. (BioWorld Today) Read More

Battered' Market Prompts LSB To Reduce Staff, Shift Resources

Lab-Grown Cholera Bacteria No Match For Natural Stool Germs, In In Vivo-In Silico Competition

LION Plans To Narrow Focus, Unload Drug Discovery Unit

TransForm, ALZA Sign Deal For Transdermal Products

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...